{
  "resourceType" : "ValueSet",
  "id" : "2.16.840.1.113762.1.4.1160.67",
  "meta" : {
    "versionId" : "7",
    "lastUpdated" : "2024-11-26T11:15:10.000-05:00",
    "profile" : [
      "http://hl7.org/fhir/StructureDefinition/shareablevalueset",
      "http://hl7.org/fhir/us/cqfmeasures/StructureDefinition/computable-valueset-cqfm",
      "http://hl7.org/fhir/us/cqfmeasures/StructureDefinition/publishable-valueset-cqfm"
    ]
  },
  "extension" : [
    {
      "url" : "http://hl7.org/fhir/StructureDefinition/valueset-author",
      "valueContactDetail" : {
        "name" : "HSAG Author"
      }
    },
    {
      "url" : "http://hl7.org/fhir/StructureDefinition/resource-lastReviewDate",
      "valueDate" : "2024-10-16"
    },
    {
      "url" : "http://hl7.org/fhir/StructureDefinition/valueset-effectiveDate",
      "valueDate" : "2024-10-16"
    }
  ],
  "url" : "http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1160.67",
  "identifier" : [
    {
      "system" : "urn:ietf:rfc:3986",
      "value" : "urn:oid:2.16.840.1.113762.1.4.1160.67"
    }
  ],
  "version" : "20241016",
  "name" : "NeuronalBlockingAgentForHypertension",
  "title" : "Neuronal Blocking Agent for Hypertension",
  "status" : "active",
  "date" : "2024-10-16T01:07:54-04:00",
  "publisher" : "American Medical Association Steward",
  "jurisdiction" : [
    {
      "coding" : [
        {
          "system" : "urn:iso:std:iso:3166",
          "code" : "US"
        }
      ]
    }
  ],
  "purpose" : "(Clinical Focus: The purpose of this value set is to represent concepts that represent medications in the Neuronal Blocking Agent pharmacologic class that are specifically indicated for the treatment of essential hypertension.),(Data Element Scope: This value set may use a model element related to Medication.),(Inclusion Criteria: Includes concepts that represent generic, human use, and prescribable medications of the Neuronal Blocking Agent pharmacologic class with a Semantic Clinical Drug (SCD) or Generic Pack (GPCK) term type that have a route of administration of: oral/pill, oral suspension, injectables, and transdermal.),(Exclusion Criteria: Excludes concepts that represent medications in the Neuronal Blocking Agent pharmacologic class with a route of administration of: ophthalmic, topical, foams, creams, and shampoo.)",
  "compose" : {
    "include" : [
      {
        "system" : "http://www.nlm.nih.gov/research/umls/rxnorm",
        "concept" : [
          {
            "code" : "198196",
            "display" : "reserpine 0.1 MG Oral Tablet"
          },
          {
            "code" : "198197",
            "display" : "reserpine 0.25 MG Oral Tablet"
          }
        ]
      }
    ]
  },
  "expansion" : {
    "identifier" : "urn:uuid:d50c515e-80cd-4d54-8eaa-50ce2737aa3b",
    "timestamp" : "2024-12-10T07:17:43-05:00",
    "total" : 2,
    "contains" : [
      {
        "system" : "http://www.nlm.nih.gov/research/umls/rxnorm",
        "version" : "11042024",
        "code" : "198196",
        "display" : "reserpine 0.1 MG Oral Tablet"
      },
      {
        "system" : "http://www.nlm.nih.gov/research/umls/rxnorm",
        "version" : "11042024",
        "code" : "198197",
        "display" : "reserpine 0.25 MG Oral Tablet"
      }
    ]
  }
}
